FIELD: medicine.
SUBSTANCE: invention is designed to prevent, slow down or relieve partial lipodystrophy in an animal. That is ensured by using an antisense compound containing a modified oligonucleotide. Said modified oligonucleotide has a nucleotide base sequence containing at least 8 adjacent nucleic bases from a nucleic acid sequence of SEQ ID NO: 3.
EFFECT: use of the invention provides effective prevention, retardation and alleviation of partial lipodystrophy.
19 cl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MODULATION OF APOLIPOPROTEIN CIII (ApoCIII) EXPRESSION | 2012 |
|
RU2603076C9 |
| MODULATING EXPRESSION OF ANGIOPOIETIN-LIKE PROTEIN 3 | 2014 |
|
RU2706964C2 |
| MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPOPROTEIN LIPASE DEFICIENT (LPLD) POPULATIONS | 2014 |
|
RU2661781C2 |
| COMPOSITIONS AND METHODS OF MODULATING APOLIPOPROTEIN C-III EXPRESSION | 2014 |
|
RU2650510C2 |
| COMPOSITIONS AND METHODS FOR MODULATING EXPRESSION OF APOLIPOPROTEIN (A) | 2014 |
|
RU2699985C2 |
| METHODS AND COMPOSITIONS FOR MODELING EXPRESSION OF APOLIPOPROTEIN (A) | 2013 |
|
RU2624028C2 |
| COMPOSITIONS FOR MODULATING EXPRESSION OF SOD-1 | 2015 |
|
RU2704619C2 |
| MODULATORS OF GROWTH HORMONE RECEPTOR | 2014 |
|
RU2700244C2 |
| ANTISENSE MODULATION OF GCGR EXPRESSION | 2012 |
|
RU2598709C2 |
| COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF DYSTROPHIC MIOTONIN-PROTEINKINASE (DMPK) | 2014 |
|
RU2690333C2 |
